Akoya Biosciences Receives Unsolicited Acquisition Proposal Amid Ongoing Merger Discussions with Quanterix

Reuters05-21

Akoya Biosciences Receives Unsolicited Acquisition Proposal Amid Ongoing Merger Discussions with Quanterix

Akoya Biosciences Inc. recently announced an update regarding its merger activities. On April 28, 2025, the company entered into an Amended and Restated Agreement and Plan of Merger with Quanterix Corporation and its subsidiary, Wellfleet Merger Sub, Inc. Under this agreement, Wellfleet Merger Sub will merge with and into Akoya, making Akoya a wholly owned subsidiary of Quanterix. Additionally, on May 20, 2025, Akoya disclosed it had received an unsolicited acquisition proposal from a third party, offering an all-cash transaction where each share of Akoya common stock would be exchanged for $1.40. Akoya's board is currently reviewing this proposal to determine if it could lead to a superior offer compared to the current merger agreement with Quanterix.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akoya Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001558370-25-008039), on May 21, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2537236989?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-21 18:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537236989","market":"us","top_or_hot":-1,"title":"Akoya Biosciences Receives Unsolicited Acquisition Proposal Amid Ongoing Merger Discussions with Quanterix","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Akoya Biosciences Receives Unsolicited Acquisition Proposal Amid Ongoing Merger Discussions with Quanterix\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Akoya Biosciences Inc. recently announced an update regarding its merger activities. On April 28, 2025, the company entered into an Amended and Restated Agreement and Plan of Merger with Quanterix Corporation and its subsidiary, Wellfleet Merger Sub, Inc. Under this agreement, Wellfleet Merger Sub will merge with and into Akoya, making Akoya a wholly owned subsidiary of Quanterix. Additionally, on May 20, 2025, Akoya disclosed it had received an unsolicited acquisition proposal from a third party, offering an all-cash transaction where each share of Akoya common stock would be exchanged for $1.40. Akoya's board is currently reviewing this proposal to determine if it could lead to a superior offer compared to the current merger agreement with Quanterix.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akoya Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001558370-25-008039), on May 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akoya Biosciences Receives Unsolicited Acquisition Proposal Amid Ongoing Merger Discussions with Quanterix</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkoya Biosciences Receives Unsolicited Acquisition Proposal Amid Ongoing Merger Discussions with Quanterix\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-21 18:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Akoya Biosciences Receives Unsolicited Acquisition Proposal Amid Ongoing Merger Discussions with Quanterix\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Akoya Biosciences Inc. recently announced an update regarding its merger activities. On April 28, 2025, the company entered into an Amended and Restated Agreement and Plan of Merger with Quanterix Corporation and its subsidiary, Wellfleet Merger Sub, Inc. Under this agreement, Wellfleet Merger Sub will merge with and into Akoya, making Akoya a wholly owned subsidiary of Quanterix. Additionally, on May 20, 2025, Akoya disclosed it had received an unsolicited acquisition proposal from a third party, offering an all-cash transaction where each share of Akoya common stock would be exchanged for $1.40. Akoya's board is currently reviewing this proposal to determine if it could lead to a superior offer compared to the current merger agreement with Quanterix.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akoya Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001558370-25-008039), on May 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QTRX","symbol_name":"Quanterix Corp","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDL4l89Df:1","article_id":"2537236989","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537236989","pubTimestamp":1747821761,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Akoya Biosciences Inc. recently announced an update regarding its merger activities. On April 28, 2025, the company entered into an Amended and Restated Agreement and Plan of Merger with Quanterix Corporation and its subsidiary, Wellfleet Merger Sub, Inc. Under this agreement, Wellfleet Merger Sub will merge with and into Akoya, making Akoya a wholly owned subsidiary of Quanterix. Additionally, on May 20, 2025, Akoya disclosed it had received an unsolicited acquisition proposal from a third party, offering an all-cash transaction where each share of Akoya common stock would be exchanged for $1.40. Akoya's board is currently reviewing this proposal to determine if it could lead to a superior offer compared to the current merger agreement with Quanterix.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"QTRX":"Quanterix Corp","AKYA":"Akoya Biosciences, Inc.","BK4121":"生命科学工具和服务","BK4539":"次新股"},"translate_title":"Akoya Biosciences在与Quanterix正在进行的合并讨论中收到主动提出的收购提案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QTRX":0.9,"AKYA":0.9},"content_text":"Akoya Biosciences Receives Unsolicited Acquisition Proposal Amid Ongoing Merger Discussions with Quanterix\n    \n\n        Akoya Biosciences Inc. recently announced an update regarding its merger activities. On April 28, 2025, the company entered into an Amended and Restated Agreement and Plan of Merger with Quanterix Corporation and its subsidiary, Wellfleet Merger Sub, Inc. Under this agreement, Wellfleet Merger Sub will merge with and into Akoya, making Akoya a wholly owned subsidiary of Quanterix. Additionally, on May 20, 2025, Akoya disclosed it had received an unsolicited acquisition proposal from a third party, offering an all-cash transaction where each share of Akoya common stock would be exchanged for $1.40. Akoya's board is currently reviewing this proposal to determine if it could lead to a superior offer compared to the current merger agreement with Quanterix.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akoya Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001558370-25-008039), on May 21, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2537236989","isCrawlerRequest":true}